INTRODUCTION
============

Protein--protein interactions are at the heart of nearly all facets of cell physiology, including transducing exogenous signals necessary for proper cell fate decisions to be adopted. For example, following exposure to cytotoxic compounds, the cell must assess the level of damage and decide whether to arrest cell division and repair the damage or execute programmed cell death. Recently, it has become apparent that intrinsic-disordered regions (IDRs), defined by a continuous stretch of disordered promoting residues, play key roles in directing protein−protein interaction networks, especially those involved in macromolecular decisions including signaling and control pathways (reviewed in [@B28]; [@B32]). This hotspot for communication is achieved in part by the ability of IDRs to contribute to the formation of large, malleable interfaces that can interact with multiple partners. These protein interactions can occur via short segments termed molecular recognition features (MoRFs) that undergo disorder-to-order transition upon binding to their cognate ligands ([@B31]). Consistent with these domains being communication hubs, the binding of IDRs to their targets is often regulated by covalent modifications including phosphorylation, which can serve as simple biological switches ([@B78]).

In budding yeast, cyclin C and its kinase partner Cdk8 are predominantly negative regulators of a diverse set of stress response genes ([@B70]; [@B19]; [@B40]; [@B15]; [@B75]). Together with Med13 and Med12, they form the Cdk8 kinase module (CKM) of the multisubunit Mediator complex, which acts as an interface between DNA bound transcription factors and RNA polymerase ([@B10]; [@B89]; [@B4]). In addition to its transcriptional role, cyclin C possesses another function following oxidative stress that is found in both yeast and mammalian cells ([@B20], [@B17]; [@B68]; [@B80]). Specifically, nuclear release of cyclin C, but not Cdk8, allows its relocalization to the mitochondrial outer membrane. At this new subcellular address, cyclin C is necessary and sufficient for stress-induced mitochondrial fission and is required for MOMP-dependent normal regulated cell death (RCD) execution ([@B20], [@B17]; [@B80]). This type of cell death is the reclassification of programmed cell death (PCD) passed by the international Nomenclature Committee on Cell Death in 2015 ([@B33]). In budding yeast, cyclin C release is dependent on its direct phosphorylation by Slt2 MAPK ([@B46]) and the ubiquitin-mediated degradation of Med13 ([@B49], and see [Figure 1](#F1){ref-type="fig"}) In the CKM, Med13 contains a large centrally located IDR, the extent and placement of which is conserved across metazoans, plants, and fungi ([@B62]). As Med13 also bridges the CKM to the Mediator complex ([@B52]) this centrally placed IDR may provide structural plasticity, allowing the CKM to interface with different mediator components according to the environment. Consistent with Med13 IDR being a potential communication hub, computer predictions suggest the presence of several MoRFs that are biased toward an alpha helical confirmation ([@B72]).

![Cdk8 module (Cdk8, cyclin C, Med12 and Med13) regulation by the CWI MAPK pathway. H~2~O~2~ stimulates cell wall sensors, leading to activation of the CWI MAP kinase module. Slt2 phosphorylation triggers cyclin C translocation to the mitochondria and Med13 degradation ([@B49]). The pseudokinase Kdx1 is also required for cyclin C nuclear release via an unknown mechanism ([@B46]). Med12 is not required for cyclin C nuclear release ([@B49]).](mbc-29-363-g001){#F1}

In this report, we provide mechanistic details on how Med13 is targeted for destruction following oxidative stress in the budding yeast *Saccharomyces cerevisiae*. We show that the cell walI integrity (CWI) pathway MAPK Slt2 directly phosphorylates Med13, which is required for its recognition by the SCF^Grr1^ E3 ligase complex. Consistent with other SCF targets in yeast and higher eukaryotes (reviewed in [@B5]), degradation of Med13 by SCF^Grr1^ also requires phosphorylation by cyclin C-Cdk8, which most likely primes this phosphodegron. Furthermore, this phosphodegron partly overlaps with the predicted Med13 IDR ([@B72]). Consistent with this region serving as an interaction hub ([@B73]), this IDR directs both Cdk8 and Grr1 binding and is sufficient to retain cyclin C in the nucleus. Taken together, these results define a multistep switch required for the cellular decision to release cyclin C from the nucleus and identify a Med13 IDR as the communication hub that coordinates this prodeath decision.

RESULTS
=======

SCF^Grr1^ is necessary for Med13 H~2~O~2~-mediated degradation
--------------------------------------------------------------

We have previously shown that Med13 degradation is dependent on a functional 26S proteasome, indicating that a ubiquitin ligase is required ([@B49]). In unstressed human cells, Med13 is turned over by the conserved SCF ubiquitin ligase utilizing the Fbw7 F-box recognition protein ([@B22]). Grr1, a yeast homologue of Fbw7, is a nonessential F-box protein that utilizes a leucine-rich region (LRR; [Figure 2A](#F2){ref-type="fig"}) for substrate recognition ([@B30]; [@B42]). SCF^Grr1^ is necessary for degradation of the mediator component Med3 ([@B38]), as well as proteins regulating the glycolytic--gluconeogenic switch ([@B9]). More recently, it has also been shown to regulate Whi7, a repressor of Start transcriptional gene expression ([@B37]). To determine whether SCF^Grr1^ plays a role in H~2~O~2~-induced Med13 degradation, we examined Med13 protein levels following 0.4 mM H~2~O~2~ treatment in wild-type and *grr1∆* cells harboring functional Med13-HA on a single copy plasmid. This concentration of H~2~O~2~ has long been established to induce a MOMP-dependent RCD response in yeast ([@B59]; [@B13]; [@B34]), as well as triggering cyclin C nuclear release ([@B20], [@B17]; [@B46]; [@B49]). The results ([Figure 2B](#F2){ref-type="fig"}) show that Med13-HA is significantly more stable in *grr1∆* cells. We next repeated these experiments using endogenous *MED13* tagged with the myc epitope in wild-type (RSY1798) and *grr1∆* mutant strains (RSY1771) harboring a plasmid expressing either wild-type *GRR1*, a vector control, or a *GRR1* derivative deleted for the LRR domain (*grr1∆L)* ([@B42]). Following H~2~O~2~ treatment, Med13-myc was again significantly more stable in *grr1∆* cells harboring either the vector control or *grr1∆L* than in wild-type cells ([Figure 2C](#F2){ref-type="fig"} and Supplemental Figure S1A). These results suggest that SCF^Grr1^ is the E3 ligase responsible for mediating Med13 degradation following H~2~O~2~ stress.

![SCF^Grr1^ mediates Med13 degradation following H~2~O~2~ stress. (A) Model of the SCF^Grr1^. (B) Wild-type (RSY10) and *grr1∆* cells (RSY1770) harboring Med13-HA (pKC801) were treated with 0.4 mM H~2~O~2~ for the time points indicated and Med13 levels were analyzed by Western blot. (C) Top panel: RSY1798 (*MED13-myc::KAN)* was treated with 0.4 mM H~2~O~2~ for the time points indicated and Med13 levels were analyzed by Western blot. Tub1 levels were used as loading controls. Bottom panel: RSY1771 (*grr1∆::HIS3 MED13-myc::KAN*) harboring *ADH1~PRO~*-*grr1∆L* was analyzed as for RSY1798. Tub1 levels were used as loading controls. (D) Yeast two-hybrid analysis of Med13 and Grr1 derivatives. Y69a cells harboring Med13-activating domain plasmid (pKC800) and either pAS2, pAS-Grr1, or pAS2-Grr1∆L binding domain plasmids were grown on *--LEU, --TRP* dropout medium to select for both plasmids (left panel) and on *--TRP, --LEU, --HIS --ADE* (middle panel), and *--TRP, --LEU, --HIS, --ADE* +3-AT (right panel) to test for Med13-Grr1 interaction.](mbc-29-363-g002){#F2}

If SCF^Grr1^ is the ubiquitin ligase directing Med13 proteolysis, then Grr1 should interact with Med13. To test this possibility, Grr1 and Med13 association was assayed using a two-hybrid strategy. This approach has been used previously both to identify and confirm Grr1 substrates ([@B81]; [@B38]). We expressed either the wild-type or the *grr1∆L* mutant *GRR1* allele fused to the Gal4 DNA-binding domain bait with the full-length Med13 fused to the activator domain (AD) prey. These studies revealed that Grr1 interacts with Med13, and this interaction survives addition of the histidine analogue 3-amino-1,2,4-triazole (3-AT), suggesting that the *HIS3* reporter gene induction is robust ([Figure 2D](#F2){ref-type="fig"}). With the *grr1∆L* mutant bait, an interaction is detected selecting for the dual *HIS3* and *ADE2* reporter genes, but colony formation is uneven (middle panel) or absent in the presence of 3-AT (right panel). Taken together with the increased stability of Med13 observed in *grr1∆* cells, these results argue that Med13 is an SCF^Grr1^ substrate.

The intrinsic disordered region of Med13 interacts with Grr1
------------------------------------------------------------

Many SCF targets require phosphorylated substrates for F-box recognition ([@B66]). Consistent with this model, the LRR of Grr1 specifically recognizes phosphorylated serine/threonine--proline motifs within its substrate degron ([@B42]). In human cells, phosphorylation of T326 is required for Med13 destruction by SCF^Fbw7^ ([@B22]). To address whether a similar mechanism directs H~2~O~2~-induced Med13 degradation in yeast, the requirement of the analogous threonine in yeast (T210; Supplemental Figure S1B) was tested. For these studies, we expressed Med13-HA from a single-copy plasmid in *med13∆* cells. These studies revealed that both the wild type and the Med13^T210A^ derivative were still degraded following 0.4 mM H~2~O~2~ stress (Supplemental Figure S1, C, D, and quantitated in E), indicating that T210 phosphorylation is not necessary for oxidative stress--induced destruction of Med13. Furthermore, consistent with our previously published results with endogenously tagged Med13-myc ([@B49]), Med13-HA degradation is not dependent on new protein synthesis, as it is still observed following cycloheximide treatment (Supplemental Figure S1C).

We next employed Y2H assays to identify the Med13 region able to interact with Grr1. Med13 has structured head and tail domains flanking a large IDR ([@B72]; [Figure 3A](#F3){ref-type="fig"}). A series of Gal4AD-Med13 constructs that span the length of Med13 were built and tested for their ability to interact with Gal4BD-Grr1. The results revealed that the Grr1 interaction domain lies within the unstructured domain, between amino acids 571 and 906 ([Figure 3B](#F3){ref-type="fig"}, summarized in [Figure 3A](#F3){ref-type="fig"}). To confirm that the Med13 degron lies within this region, we performed a classical degron assay. The levels of the prey Gal4AD-Med13^571-906^ fusion protein were monitored following 0.4 mM H~2~O~2~ stress in wild-type and *grr1∆* cells. The results indicated that Med13^571-906^ was destroyed following oxidative stress in a Grr1-dependent manner ([Figure 3C](#F3){ref-type="fig"}). Taken together, these results indicate that the SCF^Grr1^ degron lies within the IDR.

![The unstructured domain of Med13 binds Grr1. (A) ProteinPredict ([@B87]) analysis of yeast Med13. Med13 contains amino- and carboxyl-terminal structured domains separated by an intrinsic disordered domain (IDR). Grr1 and Med13 interaction regions are indicated below the schematic. ± = qualitatively reduced binding (B). Med13-Grr1 Y2H analysis. Y69a cells harboring pAS-Grr1 and the indicated Gal4AD-Med13 subclone were streaked on media selecting for plasmid maintenance (left) or induction of the *ADE2* and *HIS3* reporter genes (right) by Y2H interaction. (C) Wild-type (RSY10) and *grr1∆* (RSY1770) cells harboring the minimal Med13 interaction domain expression plasmid (Gal4AD-Med13^571--906^) were treated with 0.4 mM H~2~O~2~ for the time points indicated and Med13^571--906^ levels were analyzed by Western blot. Pgk1 levels were used as loading controls.](mbc-29-363-g003){#F3}

The Med13 intrinsic disordered region binds cyclin C
----------------------------------------------------

As cyclin C nuclear release represents an important step toward entering the cell death pathway, we next sought to identify the Med13 region that binds cyclin C, using two-hybrid strategies. However, the yeast cyclin C self-activates when tethered to a yeast two-hybrid (Y2H) bait protein ([@B19]). Therefore, we used the human cyclin C, as it does not self-activate two-hybrid reporter genes ([@B55]). Using this approach, we found that the same region associating with Grr1 (amino acid residues 571--906) also bound cyclin C ([Figure 4A](#F4){ref-type="fig"}; summarized in [Figure 3A](#F3){ref-type="fig"}). To confirm these results, as well as to address if this interaction is direct, we used a pull-down approach. We expressed a central region of the Med13 interaction domain (amino acid residues 742--844) as a GST fusion protein. GST-Med13^742-844^ was passed over a cobalt column on which *Escherichia coli*--prepared human His~6~-cyclin C was bound. Following extensive washing, bound proteins were eluted with imidazole and the presence of GST-Med13^742-844^ was determined by Western blot analysis using antibodies to His~6~ or human cyclin C. These results show that human cyclin C interacts with Med13^742--844^ ([Figure 4B](#F4){ref-type="fig"}). The experiments were repeated using yeast cyclin C ([Figure 4C](#F4){ref-type="fig"}). Although the residual cleaved GST that was present in the GST-Med13 construct showed some interaction with yeast cyclin C, the full-length construct showed a significantly stronger interaction. Confidence was gained in this interaction being specific, as no interaction was observed when GST alone was used in [Figure 4, B or C](#F4){ref-type="fig"}. Interestingly, although amino acid residues 571--650 of Med13's IDR can associate with Grr1 ([Figure 3B](#F3){ref-type="fig"}), this region does not associate with cyclin C ([Figure 4D](#F4){ref-type="fig"}). Thus, taken together, these results indicate that cyclin C binds the same region of Med13's large IDR that is recognized by SCF^Grr1^.

![The Med13 IDR binds cyclin C. (A) Y2H analysis of the human cyclin C DNA--binding domain plasmid (pSW108) and the indicated Gal4^AD^-Med13 subclone derivatives. The numbers indicate the amino acids remaining in the activation domain plasmids. Transformants were patched onto either --*LEU, --TRP* (--L--T) or --*HIS --ADE --LEU --TRP* (--H--A--L--T) to select for plasmid maintenance or Y2H interaction, respectively. (B) Western blot analysis of pull-down assays with His~6~-human cyclin C and GST-Med13^742--844^ (DS30). The load control contains 1/10 of the input. Single and double asterisks represent cleaved GST and cross-reaction between anti-GST antibody and human cyclin C, respectively. Molecular weight markers (kDa) are indicated. (C) As in B except that yeast cyclin C was used. (D) Western blot analysis of pull-down assays with GST yeast cyclin C and His~6~-Med13^571--650^ (DS22). The load control contains 1/50 of the input. Molecular weight markers (kDa) are indicated.](mbc-29-363-g004){#F4}

The Med13 intrinsic disordered region is sufficient to retain cyclin C in the nucleus
-------------------------------------------------------------------------------------

To determine whether yeast cyclin C also associates with the same region of Med13's IDR in vivo, we asked whether this region (Med13^571--906^) is sufficient to retain cyclin C in the nucleus in the absence of stress. To address this question, mitochondrial morphology and subcellular localization of a functional cyclin C-YFP ([@B20]) were monitored in unstressed *med13∆* cells harboring either a vector control or one of four Gal4^AD^-Med13 fusion proteins. As expected, cyclin C was predominantly cytoplasmic and colocalized with fragmented mitochondria in the vector control ([Figure 5](#F5){ref-type="fig"}A, top row, quantitated in [Figure 5B](#F5){ref-type="fig"}, and see Supplemental Figure S2 for DAPI stained images). Similarly, expression of Gal4AD-Med13^571--650^ was unable to retain cyclin C in the nucleus or prevent mitochondrial fragmentation (second row). However, cells expressing either Gal4AD-Med13^571--906^, Gal4AD-Med13^651--906^, or Gal4AD-Med13^742--844^ exhibited both nuclear retention of cyclin C and fused mitochondria. Taken together with the pull-down assays, these results suggest that Med13^742--844^ is sufficient to retain yeast cyclin C in the nucleus.

![The unstructured domain of Med13 retains cyclin C in the nucleus. (A) Fluorescence microscopy of mid--log phase *med13∆* cells (RSY1701) harboring the Gal4^AD^-Med13 construct indicated or a vector control (pACT2) and both cyclin C-YFP and DsRed mitochondrial targeting (mt-DsRed) plasmids. Blue boxes indicated enlarged regions of the image. Bar = 10 µM. (B) The percentage of the population of cells in A displaying at least three cyclin C-YFP foci in the cytoplasm (top panel) or fragmented mitochondria (bottom panel) is quantified (mean ± SEM). At least 200 cells were counted per time point from three individual isolates. \**p* \< 0.05 difference from vector control.](mbc-29-363-g005){#F5}

Cdk8 phosphorylation primes Med13 for destruction
-------------------------------------------------

SCF substrates are typically recognized following phosphorylation of the degron. However, many substrates require two phosphorylation marks: one to "prime" the substrate and another that represents the trigger for ubiquitylation (reviewed in [@B5]). Previous work revealed that protein kinase A (PKA) phosphorylates Med13 on Serine 608 and 1236 ([@B14]). However, a derivative mutated for both phosphor acceptor sites (Med13^S608A,S1236A^-HA) was still destroyed with kinetics similar to wild type (Supplemental Figure S3A), indicating that PKA phosphorylation is not required for Med13 degradation following H~2~O~2~ treatment. Consistent with this result, Med13^S608A,S1236A^-HA complements the aberrant mitochondrial morphology exhibit by *med13∆* cells (Supplemental Figure S3B).

In addition to PKA, cyclin C-Cdk8 phosphorylates Med13 in human cells ([@B53]; [@B65]) suggesting the possibility that Cdk8 represents the priming kinase. To test this model, Med13 destruction kinetics were monitored in a *cnc1∆* null strain transformed with either the wild-type *CNC1* gene or the vector control. These experiments indicated that cyclin C-Cdk8 kinase is necessary for Med13 destruction ([Figure 6A](#F6){ref-type="fig"} and quantified in Supplemental Figure S4A). Our previous studies showed that Slt2 phosphorylates cyclin C on Ser266 following H~2~O~2~, and this modification is required for its release from Med13 and translocation to the cytoplasm ([@B46]). Therefore, one possibility is that cyclin C release is a prerequisite for Med13 destruction. Consistent with this possibility, Med13 was protected from destruction in a *cnc1∆* mutant harboring a plasmid expressing cyclin C^S266A^ ([Figure 6A](#F6){ref-type="fig"}, right panel). These results indicate that cyclin C phosphorylation by Slt2 is also required for Med13-HA destruction (see below).

![Cyclin C-Cdk8 directly stimulates Med13 proteolysis. (A) Mid-log *cnc1∆* cultures (RSY391) harboring either wild-type *CNC1* (pKC337), vector (pRS314), or *cnc1*^S266A^ (pLR166) expression plasmids and pKC803 (CEN, Med13-HA) were subjected to an H~2~O~2~ time-course experiment. Pgk1 levels were used as loading controls. (B) Phos-tag gel analysis of pDS8 (Gal4^AD^-Med13^571--906^) in unstressed wild-type (RSY10) or *cdk8∆* (RSY1796) cultures. Arrow indicates phosphorylated Med13^571--906^ species. Molecular weight markers (kDa) are indicated. (C) RSY2066 harboring the Ubi-Ile3-Cdk8-HA expression plasmid (pCM1888) were grown to mid--log phase and doxycycline added for the indicated times. Cdk8-HA levels were monitored by Western blot analysis. Tub1 levels were monitored for loading control. (D) RSY2066 harboring pCM1888 and Med13-HA (pKC803) were grown to mid--log phase, the culture split, and doxycycline added to one for 1 h. Both cultures were then treated with 0.8 mM H~2~O~2~ and Med13-HA degradation monitored as previously described. Tub1p was monitored for loading control.](mbc-29-363-g006){#F6}

The results just presented indicated that the cyclin C-Cdk8 kinase is required for Med13 destruction in response to oxidative stress. Consistent with this, Med13 is protected from degradation in cells harboring kinase dead *cdk8* as the only source of this enzyme ([@B49]). As cyclin C-Cdk8 is active in unstressed cells, these results suggest that this kinase could prime the degron for recognition by SCF^Grr1^. To test this model, we attempted to perform in vitro kinase assays with cyclin C-Cdk8 and Med13^571--906^ as the substrate. Unfortunately, we were unable to get these assays to work. Thus we decided to examine the phosphorylation state of the Med13 degron derivative (GalADMed13^571--906^) using the Phos-Tag SDS--PAGE system, which severely retards the movement of a phosphorylated peptide ([@B51]). Protein extracts prepared from unstressed wild-type or *cdk8∆* cultures harboring GalADMed13^571--906^ were subjected to Phos-Tag Western blot analysis. The results revealed the presence of a slower migrating band in the wild-type extract that was missing in the *cdk8∆* sample ([Figure 6B](#F6){ref-type="fig"}). This indicates that Cdk8 is required for Med13 phosphorylation in unstressed cells.

To test whether cyclin C-Cdk8 activity was required before or after oxidative stress, a Cdk8-N-end rule degron was constructed. This system takes advantage of the rapid turnover of proteins that contain arginine as the amino terminal residue ([@B8]; [@B77]; [@B36]). The Cdk8-N-end rule construct is under the control of a doxycycline-repressible promoter, so that the administration of doxycycline coupled with the rapid turnover of the Cdk8-N-end rule fusion protein results in rapid depletion of Cdk8 from yeast cells ([Figure 6C](#F6){ref-type="fig"}). To test the execution point for Cdk8 phosphorylation, a mid--log culture expressing Med13-HA and Cdk8-N-end degron was untreated or treated with doxycycline for 1 h prior to H~2~O~2~ addition to ensure Cdk8 depletion. A time course was conducted and samples were collected, extracts prepared, and Med13-HA levels monitored by Western blot analysis. These studies revealed that Med13-HA levels were reduced similarly in both cultures ([Figure 6D](#F6){ref-type="fig"}), indicating that Cdk8 function was required before oxidative stress. Taken together, these results are consistent with a model in which Cdk8 phosphorylation primes Med13 for degradation.

The CWI pathway is required for reactive oxygen species--mediated destruction of Med13
--------------------------------------------------------------------------------------

The CWI signal transduction pathway is the major MAPK pathway in yeast that transmits the reactive oxygen species (ROS) stress signal to transcription factors ([@B67]). To facilitate cyclin C nuclear release, the CWI employs two MAPKs, Slt2 and its pseudokinase paralogue Kdx1. Slt2 phosphorylates cyclin C on Serine 266 to induce cytoplasmic relocalization ([@B20]; [@B45], [@B46]), while Kdx1 functions through an unknown mechanism ([@B44]). To address the question of whether Kdx1 and/or Slt2 is required for Med13 degradation, we examined Med13-HA degradation kinetics in wild-type and *slt2∆* or *kdx1∆* single-mutant cultures following 0.4 mM H~2~O~2~ stress. As *slt2∆* mutants are temperature-sensitive, these experiments were conducted at 23°C. The results show that Med13-HA was degraded in wild-type or *kdx1∆* cells but stable in the *slt2∆* mutant ([Figure 7A](#F7){ref-type="fig"}, quantified in Supplemental Figure S4B). These results indicate that unlike cyclin C, only Slt2, but not Kdx1, is required for Med13 destruction. Repeating this experiment with cells expressing a kinase-dead version of *SLT2* (*slt2*^K54R^) produced similar results ([Figure 7B](#F7){ref-type="fig"}), indicating that Slt2 kinase activity is required for Med13 proteolysis. To investigate whether the role of Slt2 in Med13 degradation was direct, in vitro kinase assays were performed using activated Slt2-HA or the kinase-dead derivative (Slt2^K54R^-HA; [@B50]) immunoprecipitated from yeast extracts. The immunoprecipitate was incubated with the *E. coli* prepared Med13 degron (amino acids 571--906) described above. These experiments revealed enhanced phosphorylation of Med13^571--906^ above background that was dependent on a functional kinase ([Figure 7C](#F7){ref-type="fig"}), indicating that Slt2 directly regulates Med13 stability. Finally, we asked whether Slt2 activation was sufficient to induce Med13 destruction or whether another stress signal was required. To address this question, Med13-HA levels were monitored in an unstressed culture expressing a constitutively active allele of the upstream MAPKKK *BCK1* (*BCK1-20*). Mid-log cultures expressing *BCK1-20* exhibited dramatically reduced Med13-HA levels compared with vector controls ([Figure 7D](#F7){ref-type="fig"}). These results indicate that the CWI pathway is both necessary and sufficient to induce Med13 destruction. Finally, to test the epistatic relationship between *BCK1-20* and *cdk8∆* alleles, the experiment just described was repeated in a *cdk8∆* background. Western blot analysis revealed that Cdk8 was required for *BCK1-20*-induced Med13 destruction in unstressed cells ([Figure 6D](#F6){ref-type="fig"}). Taken together, these results indicate that Slt2 activation is necessary for H~2~O~2~-mediated Med13-HA degradation and that this signal requires Cdk8 activity. These results are consistent with a three-step model for initiating the Med13 destruction pathway (see the *Discussion*).

![Slt2 directly stimulates Med13 destruction. (A) Wild-type (RSY10), *kdx1∆* (RSY1736) and *slt2∆* (RSY1006) cultures expressing pKC801 (CEN, Med13-HA) were grown to mid--log phase (0 h) and then treated with 0.4 mM H~2~O~2~ for the indicated times. Med13-HA levels were determined by Western blot analysis. (B) As in A except that the *slt2∆* cells expressed a kinase dead *SLT2* mutant (*slt2*^K54R^) plasmid. (C) Top panel: Slt2-HA or Slt2^K54R^-HA (kinase dead) was immunoprecipitated from extracts prepared from cells treated for 60 min with 5 mM sodium orthovanadate was mixed with Med13^571--906^ and radioactive ATP as indicated. All reactions were conducted in duplicate and then separated by SDS PAGE and subject to autoradiography. Med13^571--906^ is indicated by the arrowhead. Bottom panel: Coomassie stained gel showing the Med13^571--906^ input used in the kinase assays. (D) Wild-type (RSY10) or *cdk8∆* (RSY1796) mutant cells expressing either an empty vector control or the hyperactive allele of *BCK1* (*BCK1-20*) and *MED13*-HA (pKC803) were grown to midlog and Med13-HA levels determined by Western blot analysis. Tub1 served as a loading control.](mbc-29-363-g007){#F7}

Slt2 and Cdk8 phosphorylation of the intrinsic disordered region is required for Med13 destruction
--------------------------------------------------------------------------------------------------

IDRs confer conformational flexibility on proteins that are often targets of posttranslational modifications ([@B24]). Notably, IDRs are enriched in phosphorylation sites, raising the possibility that they are substrates for multiple kinases ([@B16]). As our data indicate that Cdk8 and Slt2 are required for Med13 degradation, we next asked if the sites they phosphorylate lie within the same IDR of Med13 that associates with Grr1 and cyclin C (amino acids 651--906). Slt2 and Cdk8 are both proline-directed kinases that preferentially phosphorylate the consensus sequences PX(S/T)P and S/T-P-X-K/R (where X is any amino acid), respectively. They also can phosphorylate the minimal consensus sequence S/T-P ([@B64]). Med13^651--906^ contains a conserved Slt2 consensus sequence at position 748 that has been identified as potential phosphorylation site in two genomic screens ([@B3]; [@B41]) as well as four additional TP sites ([Figure 8A](#F8){ref-type="fig"}). Thus, to address whether these kinases phosphorylate the five S/T-P sites in Gal4^AD^-Med13^651--906^ fusion protein, its degradation was monitored following H~2~O~2~ stress in wild-type, *slt2∆* and *cdk8∆* cells. The results show that Gal4AD-Med13^651--906^ fusion protein is stable in either *slt2∆* or *cdk8∆* cells ([Figure 8B](#F8){ref-type="fig"}). These results are consistent with a model where the Med13 phosphodegron is targeted by both Cdk8 and Slt2. Consistent with the Y2H data presented in [Figure 3B](#F3){ref-type="fig"}, the phosphodegron is stable in *grr1∆* cells ([Figure 8C](#F8){ref-type="fig"}). If the Med13 phosphodegron is regulated by two kinases, then two separate S/T-P sites within the degron should stabilize the protein. To test this, wild-type cells harboring either a wild-type Gal4AD-Med13^742--844^ fusion protein or mutant derivatives were subjected to 0.4 mM H~2~O~2~ stress and analyzed as described above. As anticipated, the smaller Gal4AD-Med13^742--844^ fusion protein that contains all five S/T-P sites was still degraded in wild-type cells ([Figure 8C](#F8){ref-type="fig"}). Interestingly, the S748A, T781A, and T803A mutants were also degraded, with the same kinetics as wild type (Supplemental Figure S4C). In addition, the double mutants (T781A, T803A and S748A, T781A) were also degraded with wild-type kinetics ([Figure 8, D and E](#F8){ref-type="fig"}). However, the T835A, T837A double mutant was significantly more stable than the wild type ([Figure 8, C and E](#F8){ref-type="fig"}), suggesting that these sites are needed for Med13 degradation. Taken together, these results suggest that both kinases have to be active for SCF^Grr1^ to recognize this 100--amino acid phosphodegron at positions T835 and T837.

![The Med13 IDR contains the phosphodegron. (A) Map of Med13 showing the location of potential Cdk and MAPK sites within the IDR. (B) Wild-type (RSY10), *slt2∆* (RSY1737), and *cdk8∆* (RSY1796) cultures expressing pDS16 (Gal4^AD^-Med13^651--906^) were grown to mid--log phase (0 h) and then treated with 0.4 mM H~2~O~2~ for the indicated times. Med13^651--906^-HA levels were determined by Western blot analysis. Pgk1 levels were used as a loading control. (C, D) Wild-type (RSY10) cultures harboring wild-type Gal4AD-Med13^742--844^ (pDS32) or various point mutations as indicated were grown to mid--log phase (0 h) then treated with 0.4 mM H~2~O~2~ for the indicated times. Med13-HA levels were determined by Western blot analysis. Pgk1 levels were used as a loading control. The Gal4AD-Med13^742--844^ levels were also monitored in the *grr1∆* strain. (E) Degradation kinetics of the Gal4AD-Med13^742--844^ constructs shown in C and D.](mbc-29-363-g008){#F8}

DISCUSSION
==========

Communication between organelles is critical to coordinate the cellular response to a variety of external or internal signals, including oxidative stress. The data presented here and in previous publications ([@B19], [@B17]; [@B55]; [@B45], [@B46], [@B44]; [@B49]; [@B80]) have revealed that the CKM plays a key role in both yeast and mammalian cells. Previously, we reported that cyclin C, but not Cdk8, translocates from the nucleus to the mitochondria following oxidative stress in both yeast and mammalian cells. At the mitochondria, cyclin C associates with the fission machinery to induce fragmentation and directs programmed cell death ([@B20], [@B17]; [@B80]). Therefore, releasing cyclin C from the nucleus represents an important step determining whether the cell initiates the RCD pathway or not. Importantly, we found that the nuclear anchor for cyclin C, Med13, is destroyed in response to oxidative stress, providing a mechanism for orchestration of cyclin C nuclear release ([@B49]). Interestingly, Med12 is neither required for this response ([@B49]) nor destroyed following H~2~O~2~ stress (Supplemental Figure S4D). In this report, we provide the molecular details on how Med13 destruction is triggered to operate this important molecular switch in yeast. First, Med13 proteolysis is mediated by the ubiquitin ligase SCF and the specificity factor Grr1. Several studies in yeast and higher eukaryotes found that SCF substrates require a complex interplay between multiple kinases to generate the requisite phosphodegron on the substrate (reviewed in [@B5]). For example, Cdk1 acts as a priming kinase for Cdc5 ([@B7]; [@B90]), whereas Cdc5 acts as a priming kinase for Wee1 ([@B82]). In all cases, the priming kinase first phosphorylates the substrate, while the second kinase completes the formation of the phosphodegron by modifying residues that are recognized by the SCF. This has led to the current model, in which priming phosphorylations create docking sites for downstream kinases. Moreover, local structural disorder most likely facilitates multiple kinases regulating a protein within a small region. We identified a small region (amino acids 742--844) within the IDR of Med13 that acts as a communication hub. This region is sufficient to retain cyclin C in the nucleus, associates with Grr1, and contains the Med13 phosphodegron that is primed by Cdk8 and activated by Slt2 following oxidative stress exposure. This dual kinase requirement provides the cell with a mechanism to integrate multiple input signals into a single readout.

Med13 phosphodegron activation requires a three-step process
------------------------------------------------------------

Our results indicate that cyclin C-Cdk8 provides the priming signal for Med13 destruction ([Figure 9](#F9){ref-type="fig"}, Step 1). Although technical reasons prevented us from addressing whether this activity is direct or indirect, four independent experiments support a model of this as a direct phosphorylation event: 1) The observation that Med13^651--906^ was not destroyed following H~2~O~2~ stress in *cdk8∆* cells ([Figure 8B](#F8){ref-type="fig"}). 2) The observation of a slower migrating band seen in Phos-Tag SDS--PAGE analysis of unstressed in wild-type extracts that was missing in the *cdk8∆* sample ([Figure 6B](#F6){ref-type="fig"}). 3) The end-N rule experiments conducted in [Figure 6, C and D](#F6){ref-type="fig"}, also revealed that Med13-HA levels were reduced regardless of the presence of Cdk8 after stress. 4) Last, in vitro evidence revealed that cyclin C interacts directly with this region of Med13 ([Figure 4, B and C](#F4){ref-type="fig"}), which would position the kinase with direct access to the Med13 degron. Thus, taken together, these results suggest that Cdk8 phosphorylation primes Med13 for degradation, most likely by a direct event. Consistent with this, human Cdk8 directly phosphorylates human Med13 on S749, which lies in the intrinsic disorder domain in what appears to be a nonconserved residue compared with yeast ([@B65]). This requirement may be necessary to inform the cell that Med13 is in the Cdk8 module and its destruction will lead to cyclin C release and Cdk8 inactivation. Slt2 activation by oxidative stress provides the trigger mechanism that commits the cell to destroying Med13 and releasing cyclin C from the nucleus (Step 3). This event accomplishes two goals. First, removing cyclin C and destroying Med13 inhibits the repressor activity of Cdk8 for several stress-­responsive genes, including chaperones (e.g., *SSA1*), anti-oxidants such as catalase (*CTT1*), and the multi-stress-responsive gene *DDR2* ([@B19], [@B20]; [@B40]). In addition, Slt2 activation stimulates several transcription factors, such as Rlm1, which is required for the transcriptional arm of the stress response ([@B25]; [@B83]; [@B47]). Therefore, Slt2 activation both stimulates transcriptional activators and inhibits repressors. By releasing cyclin C, the cell is able to transmit the stress signal to the mitochondria. We have previously demonstrated that cyclin C--induced fission alone is not sufficient to induce cell death, but does make cells hypersensitive to oxidative stress ([@B49]). Therefore, cyclin C release poises the cell to initiate RCD, but additional regulatory layers exist. Unlike other priming/trigger two-kinase degron phosphorylation switches, we have identified an additional step in the system regulating Med13. Specifically, Slt2 also modifies cyclin C on S266, which promotes its dissociation from Med13 ([@B46]). Our finding that the S266A mutation protects Med13 from destruction is consistent with a model in which S266 modification disrupts cyclin C--Med13 interaction (Step 2), allowing Slt2 access to the phosphodegron. Taken together, our model predicts a three-step system that controls Med13 stability and cyclin C nuclear release.

![Three-step model of cyclin C release from Med13 following H~2~O~2~ stress. Step 1: Cdk8-cyclin C kinase phosphorylates Med13 in unstressed cells to provide the priming modification for this degron. Step 2 requires stress-activated Slt2 that phosphorylates cyclin C on S266 leading to dissociation of cyclin C from Med13. This event allows Slt2 access to the phosphodegron to deliver the trigger modification leading to Med13 recognition by SCF^Grr1^ and its destruction (Step 3).](mbc-29-363-g009){#F9}

If cyclin C phosphorylation is sufficient to initiate cyclin C nuclear release, then why would it be important to completely destroy Med13? First, our results indicate that S266 phosphorylation is capable of stimulating only partial release of cyclin C in unstressed cells ([@B46]). Therefore, Med13 destruction may be necessary for complete cyclin C release. Not exclusive of this model, another possibility is that Med13 destruction prevents the reaccumulation of cyclin C in the nucleus after its cytoplasmic translocation. In this model, Med13 proteolysis fixes the decision of cyclin C release thus directing a complete transcriptional and mitochondrial response to oxidative stress.

The Med13 intrinsic disordered region is a communication hub
------------------------------------------------------------

It has recently been suggested that IDRs play important roles in protein:protein communication, as they provide a flexible interaction surface to multiple partners ([@B86]). Using two different protein structure prediction algorithms, IUPred/ANCHOR and Phyre^2^ ([@B26], [@B27]; [@B48]), Med13 has a large IDR spanning the middle of the protein (amino acids residues 307--906 and Supplemental Figure S5, A and B). Although not conserved in amino acid sequence, it is notable that the position and presence of Med13's IDR is conserved throughout three kingdoms ([@B62]). Also conserved is the observation that Med13 is the CKM member that brings this kinase module in contact with the Mediator complex ([@B52]). This suggests a model in which the IDR of Med13 provides conformational plasticity to the CKM, which is important for bringing the kinase and other proteins into contact with different mediator members on a *pro re nata* basis. This idea is consistent with the results presented here, in which we show that the IDR of Med13 can bind to cyclin C before stress and Grr1 after. Although speculative, taken together, this suggests a model in which Med13 IDR is conserved functionally and may contain signature motifs that are important for protein binding. Consistent with this idea is the observation that two other conserved proteins that regulate transcription (CCR4-NOT4 and TFIIS) also bind to the IDR of yeast Med13, but in a different location (Supplemental Figure S5; [@B57]; [@B85]). Such a signature could be a MoRF, which is defined as a short binding region located within a longer intrinsically disordered region that binds to protein partners via disorder-to-order transitions ([@B54]). ANCHOR analysis ([@B27]) predicts that the IDR of Med13 has many such domains, with two lying within the cyclin C binding region (residues 742--844, Supplemental Figure S5A). As additional factors are identified that bind the Med13 IDR, the rules that govern these interactions may become better understood.

The need to understand the role that Med13 IDR plays in protein communication has become important in the past decade, as in humans truncating or loss-of-function mutations in *MED13L*, a paralogue of *MED13* ([@B61]), results in *MED13L* haploinsufficiency syndrome. This syndrome is complex and presents with a range of symptoms including congenital heart and neurodevelopmental defects, severe neurocognitive deficiencies, and facial dysmorphism ([@B1]; [@B76]; [@B6]; [@B88]). Interestingly many of these mutations lie in the IDR of MED13L ([@B6]). In yeast, a hallmark of *med13∆* cells is that they are respiratory deficient, which is dependent on cyclin C nuclear release ([@B49]). Thus, it would be anticipated that a strain deleted for Med13 residues 742--844 would have a similar phenotype. Taken together, these studies emphasize the need for further analysis of both yeast and human Med13 IDRs to understand the molecular details of how this region contributes to Med13 function.

Role of SCF^Fbw7^ and Med13 in higher eukaryotes following stress
-----------------------------------------------------------------

Our previous studies described the conserved role of cyclin C in stressed and unstressed cells ([@B17]; [@B80]). However, differences are observed between yeast and humans in cyclin C regulation. In yeast, all of cyclin C is released into the cytoplasm, followed by its destruction by the Not1 ubiquitin ligase. Conversely, only ∼10% of total cyclin C is released from the nucleus in mammalian cells following oxidative stress, and we do not detect any significant changes in its overall protein levels ([@B80]). Steady state turnover of the human Med13 is directed by the analogous SCF ubiquitin ligase by a homologue of Grr1, called Fbw1 ([@B22]). As Med13 tethers the Cdk8 module to the Mediator complex ([@B52]), Med13 turnover determines the promoter residency of the module and therefore impacts transcriptional regulation. However, we found that the phosphodegron directing the turnover of Med13 in human cells (T326) is not required for stress-induced destruction of Med13 in yeast. These results suggest either that a different degron system is employed in these two systems or that stress-induced destruction is regulated differently than that observed under normal growth conditions. Consistent with this is the observation that Cdk substrates are often clustered in regions of intrinsic disorder (reviewed in [@B29]). However, similar to other IDRs, their exact position in the protein is often poorly conserved in evolution, indicating that precise positioning of phosphorylation may not be required to permit a shared function (reviewed in [@B29]). Thus, it is possible that following oxidative stress in human cells, a similar two-kinase mechanism could regulate Med13 degradation. In support of this model, phosphorylation by two kinases has been observed for other SCF^Fbw7^ substrates ([@B2]) including oncogenic transcription factors. This has led to Fbw7 being classified as a tumor suppressor (reviewed in [@B84]). Fbw7 degrades numerous oncogenic transcription factors (e.g., Myc, Notch, and Jun), as well as other proteins that contribute to carcinogenesis. As cyclin C has also recently been given this tumor suppressor designation ([@B56]), it is imperative to understand the relationship between these proteins following stress in higher eukaryotes.

MATERIALS AND METHODS
=====================

Yeast strains and plasmids
--------------------------

All experiments, except the Y2H assays, were performed on the *S. cerevisiae* W303 strain RSY10 ([@B69]) and are listed in Supplemental Table S1. The Y2H assays were performed on PJ69-4a ([@B43]). In accordance with the Mediator nomenclature unification effort ([@B11]), cyclin C (*SSN8*/*UME3*/*SRB11*) and Cdk8 (*SSN3*/*UME5*/*SRB10*) will use the *CNC1* and *CDK8* gene designations, respectively. For reference, the human cyclin C gene name is *CCNC*. The *cnc1∆, cdk8∆, med13∆, slt2*∆, *kdx1∆*, and *kdx1 slt2∆* strains have been previously described ([@B19], [@B17]; [@B55]; [@B46]). The *grr1∆* strain RSY1770 and the myc-,tagged Med12 strain (RSY1787) were constructed using gene replacement methodology as described ([@B58]). The *MED13-*13myc allele was generated in RSY1770 to create RSY1771 using the same methodology. RSY2066 was made by integrating pMK634 ([@B36]) into the *CDK8* locus of RSY10. The strain was then transformed with pCM188 ([@B35]), which contains the TET activator on a plasmid. The yeast hybrid strain PJ69-4a was obtained from the Yeast Resource center, courtesy of a gift from S. Fields (University of Washington). All cells were grown at 30°C, apart from *slt2∆* and *slt2∆ kdx1∆*, which were grown at 23°C.

All plasmids used in this study are listed in Supplemental Table S2. The wild-type epitope tagged plasmids pHY1066 (*MED13-*HA, 2 µ), pKC337 (*ADH1*~Pro~-cyclin C-myc), pUM511 (*GPD1*~Pro-~*CDK8*-HA), and pBK38 (*ADH1~Pro~*-*CNC1*-YFP) are functional and have been described previously ([@B19], [@B20]; [@B21]; [@B14]; [@B45]). pLR141 was made by cloning the *ADH1*~Pro~-*CNC1*-myc, CYC~Term~ from pKC337 into pRS426. The 2 µ *MED13*-HA plasmids (PHY1066 and PHY1089) and were a gift from P. Herman (Ohio State University) ([@B14]). The wild-type *MED13* centromere--based plasmids pKC801 and pKC803 were made by PCR cloning the *ADH1* promoter *MED13-*3HA ORF and the *MED13* terminator from PHY1022 into pRS316 and pRS315, respectively. Site-directed mutagenesis (New England Bio-Rad Q5) was used to create plasmids harboring amino acid mutations, except for DS36 which was made using the Change-IT kit by Affymetrix. The *CNC1*^S266A^ and the *SLT2*^K54R^ (a gift from D. Levin, Boston University) have been described previously ([@B50]; [@B46]). The *MED13* Y2H plasmids were constructed by PCR cloning from pHY1022 into the *Xho*1 site of the Gal4 activating domain plasmid pACT2. Likewise, the human cyclin C Y2H Gal4 binding domain plasmid pSW108 was made by PCR cloning of cyclin C cDNA amplified from pEGFP-cyclin C (unpublished data) into *Nco*1-digested pAS2. The GST-*MED13* fusion plasmid was made by PCR cloning from PHY1022 into pGEX4T-1. Oligonucleotide sequences were used to make plasmids, and strains are available upon request. In short, all constructs were amplified from plasmid DNA using Phusion Taq (Thermo) digested using NEB fast digest restriction enzymes and ligated using Thermo fast ligase into their respective vectors. All protein fusion constructs were sequenced (Eurofins Genomics). Other plasmids that were used in this study that have been previously described are listed in Supplemental Table S2.

Cell growth
-----------

Yeast cells were grown in either rich, nonselective medium (YPDA) or synthetic minimal medium (SC), allowing plasmid selection as previously described ([@B19]). For all experiments, the cells were grown to mid--log phase (∼6 × 10^6^) before treatment with low concentrations of 0.4 mM H~2~O~2~, as previously described ([@B45]). Samples of 25 ml of cells were collected per time point and washed in water; then the pellets were flash frozen in liquid nitrogen. Y2H experiments were executed as described ([@B81]). A sample of 10 mM 3-amino-1,2,4-triazole (3-AT) was added to the selective plates to increase the stringency of the interactions. *E. coli* cells were grown in LB medium with selective antibiotics. The degron experiments described in [Figure 5, D and E](#F5){ref-type="fig"}, were executed as follows. In [Figure 5D](#F5){ref-type="fig"}, cells (RSY2066) were grown to midlog and samples removed at the time points shown for analysis of Ubi-isoleucine::3HA-Cdk8 degradation after the addition of 2 µg/ml doxycycline. In [Figure 5E](#F5){ref-type="fig"}, RSY2066 was transformed with Med13-3HA plasmid (pKC803), grown to midlog, and split and into one flask 2 µg/ml doxycycline was added. After 60 min, 0.8 mM H~2~O~2~ was added to both sets of cells and samples taken for NaOH lysis and Western analysis as described below.

Western blot analysis
---------------------

Tagged Med13 constructs were detected using NaOH lysis of cell pellets as described by [@B91]. In short, the frozen cell pellets were defrosted on ice, resuspended in 2 M LiOAc on ice for 5 min, centrifuged, and then resuspended in 0.4 M NaOH for a further 5 min on ice. Thereafter, the pellets were resuspended in 100 µl 2X SDS loading dye ([@B19]) and boiled for 5 min, and 15 µl was loaded onto a 6% SDS--PAGE gel (Novagen). For the phos-tag gel ([Figure 9B](#F9){ref-type="fig"}), proteins were prepared as just described and analyzed on a 7.5% polyacrylamide gel containing 7.5 µM phos-tag (Wako Laboratory Chemicals) and 15 µM MnCl~2~. The proteins were transferred to a nylon membrane (Millipore) using 10% methanol, 0.02% SDS, and 10X running buffer ([@B19]). To detect Med13-myc, Med12-myc, and Med13-HA, 1-in-5000 dilutions of either anti-myc (Roche) or anti-HA antibodies (Clontech) were used. Tub1 and Pgk1 were visualized as previously described ([@B71]), except that anti--alpha tubulin antibodies (12G10) were obtained from the Developmental Studies Hybridoma Bank, University of Iowa. Western blot signals were detected using either goat anti-mouse or goat anti-rabbit secondary antibodies conjugated to alkaline phosphatase (Sigma) and the CDP-Star chemiluminescence kit (Tropix). Signals were quantitated by CCD camera imaging (Kodak). All degradation assays were performed more than once. SEM were generated for each point and error bars are indicated on the graphs, which were generated using the GraphPad Prism 7 program.

Fluorescence microscopy
-----------------------

YFP-cyclin C subcellular localization and mitochondrial morphology were monitored as described previously ([@B20], [@B17]). For all experiments, the cells were grown to midlog (6 × 10^6^ cells/ml), treated with 0.4 mM H~2~O~2~ for the time points indicated, and then analyzed by fluorescence microscopy. Cyclin C-YFP export analysis was performed on cells fixed with 4% paraformaldehyde/3.4% sucrose for 1 h at room temperature. The cells were washed three times in water and prepared for fluorescence microscopy as described previously ([@B39]) using mounting medium (10 mg/ml *p*-phenylenediamine, 50 ng/ml 4′,6-diamidino-2-phenylindole \[DAPI\]) to visualize nuclei and prevent photo bleaching. Images were obtained using a Nikon microscope (Model E800) with a 100× objective with 1.2× camera magnification (Plan Fluor Oil, NA 1.3) and a CCD camera (Hamamatsu Model C4742). Data were collected using NIS software and processed using Image Pro software. All images of individual cells were optically sectioned (0.2 µM slices at 0.3 µM spacing) and deconvolved, and the slices were collapsed to visualize the entire fluorescent signal within the cell. Cyclin C-YFP foci were scored as being cytoplasmic when three or more foci were observed outside the nucleus. Mitochondrial fission assays were performed on live cells as described ([@B17]). In brief, mitochondrial fission was scored positive if no reticular mitochondria were observed that transversed half the cell diameter. Fusion was scored when cells exhibited one or more reticular mitochondria the diameter of the cell. Fission and fusion was scored for 200 cells from three independent isolates. Statistical analysis was performed using Student's *t* test, with *p* \< 0.05 used to indicate significant differences.

Pull-down assays and kinase assays
----------------------------------

Purified proteins that were used in the pull-down assay ([Figure 4B](#F4){ref-type="fig"}) were made as follows. The GST constructs (DS30, GST hCCNC, and GST alone) were transformed into the BL21 DE3 *E. coli* strain and expression was induced with 0.5 M IPTG at 37°C for 3 h. Cell pellets were resuspended in 50 ml GST lysis buffer (150 mM KCl, 50 mM HEPES, pH 7.5, 1 mM βME) and sonicated (25 × 10 s bursts), and the supernatant was recovered by centrifugation at 40,000 × *g* for 30 min. The supernatant was then added to 1 ml of washed glutathione beads (LifeTech) rotated at 4°C for 1 h. The unbound fraction was removed from the beads by gravity flow. The beads were washed twice with lysis buffer and the bound protein was eluted in five 1 ml fractions with the elution buffer (lysis buffer supplemented with 10 mM reduced glutathione). The protein-containing fractions were pooled and then desalted using 4 ml Zebra7K desalting columns that had been preequilibrated with the lysis buffer. The protein fraction was supplemented with glycerol to a final concentration of 10% and stored at --80°C in small aliquots. His~6~ tagged human or yeast cyclin C was purified the same way with the following exceptions. The lysis buffer (buffer A) was 500 mM KCl, 50 mM HEPES, pH 7.5, 1 mM βME, and 20 mM imidazole. Talon beads (Clontech) were used and washed with buffer B (150 mM KCl, 50 mM HEPES, pH 7.5, 1 mM βME , and 20 mM imidazole) and the bound protein was eluted in elution buffer (150 mM KCl, 50 mM HEPES, pH 7.5, 1 mM βME, and 500 mM imidazole). The desalting columns were preequilibrated with the B buffer without imidazole. The concentrations of all the recombinant proteins were determined by Bradford assay. The pull-down assays in [Figure 4, B and C](#F4){ref-type="fig"}, were performed using His~6~-tagged human or yeast cyclin C, respectively, as bait and GST-tagged Med13^742--844^ (DS30) as target. A quantity of 500 nM cyclin C was mixed with 1 μM of Med13^742--844^ in a final reaction volume of 250 µl with B buffer and incubated for 1 h at room temperature. Bound protein was precipitated with 100 µl of washed Talon beads and eluted using 500 mM imidazole. The protein mixture was resolved using SDS--PAGE and Western blotting with either anti-GST (Abcam), anti-His (Bethal), or anti--human cyclin C antibodies (Bethal). Controls with only the target protein and no bait protein were included in all the experiments. The pull-down assays in [Figure 4D](#F4){ref-type="fig"} were performed using 500 nM of either GST or GST-tagged yeast cyclin C and 1 µM His~6~-Med13^571--660^ (DS22). The proteins were incubated together in GST lysis buffer and incubated at RT for 1 h. Then 100 μl of GSH beads (preequilibrated with GST wash/lysis buffer) was added to the protein mixture and incubated with rotation for 1 h. The beads were centrifuged for 30 s washed twice with 500 μl of GST wash/lysis buffer. The protein mixture was resolved using SDS--PAGE and Western blotting with either anti-GST or anti-His antibodies.

The in vitro kinase assays were executed basically as described by [@B23]. Slt2-HA and Slt2^K54R^-HA kinases were immunoprecipitated from cells treated with 5 mM sodium orthovanadate for 60 min, which activates Slt2 ([@B60]). In short, yeast extracts harboring the respective plasmids were made by resuspending cells in lysis buffer (20 mM HEPES, 10 mM KCl, 1 mM EDTA, 1 mM ethylene glycol tetraacetic acid \[EGTA\], 50 mM NaCl, 10% glycerol, 1 mM β-mercaptoethanol, and cOmplete Protease Inhibitor Cocktail Tablet, pH 7.4, with phosphatase inhibitors for Cdk8-HA purification) and protein immunoprecipitation was conducted as previously described ([@B23]), with anti-HA magnetic beads (PierceTM)/anti-myc magnetic beads (Cell Signaling). Med13^571--906^ was purified from an *E. coli* BL21 DE3 strain induced with 0.5 mM IPTG for 5 h at 37°C using the 6X His-tagged purification method previously described ([@B23]). The Slt2 in vitro kinase assay was conducted as previously described ([@B12]) by resuspending Slt2 beads in kinase buffer (20 mM HEPES, 10 mM MgCl~2~, 100 μM Na~3~VO~4~, pH 7.5), with 20 μM ATP, 5 μCi of 32P-ATP, and purified Med13^571--907^. Reactions were incubated at 30°C for 30 min.
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